Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva alone vs Tarceva plus VELCADE in NSCLC
NCT00283634Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by Millennium Pharmaceuticals. Started Aug 2005; status: terminated.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00283634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283634.